Our mission at Alcyomics is to provide novel solutions for the assessment of safety and efficacy of pharmaceuticals, cosmetics and chemicals.
As a service provider Alcyomics aspires to take the lead in providing unique screening services enabling more cost-effective commercialisation of products and or drugs offering a reliable alternative to animal testing for safety and potency assessment of novel compounds. We use our patented technology, Skimune®, a non-artificial human skin explant test to accurately predict adverse immune reactions. For example we can assist in clinical trial development by evaluation of dose response. We work to Good Laboratory Practice and to ISO9001 standards and our safety and efficacy reports have been submitted to regulatory authorities to support, for example clinical trial applications.
Skimune® represents the fruits of over 30 years’ research on haematopoietic stem cell transplantation and Graft versus Host Disease (GvHD) by Alcyomics CEO, Anne Dickinson Emeritia Professor of Translational and Clinical Medicine at Newcastle University, who used human skin based in vitro assays for identifying responses of donor cells against patient skin tissue i.e. graft versus host disease (GvHD) following haematopoietic stem cell transplantation. Her research work that has been extensively published in over 100 peer-reviewed journals. This skin explant predictive assay for GvHD has been used in Newcastle as part of a clinical protocol for treatment of haematological disorders and has been published to have a >80% correlation with clinical outcome. Since GvHD affects more than one target organ e.g. skin, gut and liver, the assay is predictive of systemic disease.
In 2007, Anne realised the commercial potential of human skin based in vitro models for predicting adverse immune responses. She went on to create Alcyomics Ltd as a spin out of Newcastle University.
Since the incorporation of the company, the service portfolio has significantly increased by the development of invitro models of disease e.g. atopic dermatitis, osteoarthritis and innervated models for drug discovery and efficacy testing. Our drive to extend our service offerings continues with an excellent team of experienced scientists.
If you would be interested in finding out more about Alcyomics please contact us.
Management and Scientific Teams
Alcyomics brings the wealth of knowledge and expertise from Prof. Dickinson, using her knowledge from a career as a Health Professional Clinical Scientist and Director of Newcastle Cellular Therapy Facility (until her retirement in August 2019) and her direct experience in the regulatory framework involved in Good Manufacturing Practice (GMP) for the development of Advanced Therapy Medicinal Products (ATMPs). We work hard to ensure our team is made up of experts in all relevant fields, from scientific expertise in cell bioprinting, disease modelling, wound healing, neurotoxicity and immunotoxicology to managerial expertise, ensuring smooth project management, quality control, reporting and communication.
Alcyomics will ensure that the unique requirements of every client are catered for in a bespoke project plan to meet objectives and deliverables. Our CEO has over 30 years experience in managing multi million-pound European Commission consortia projects, working with multi disciplinary teams from within UK and Europe. We manage commercial grants, in addition to grants funded by Innovate UK, NC3R’s, and Advanced Manufacturing Supply Chain Initiative. Alcyomics have worked with some of the top 10 pharma and cosmetic companies globally
EU Skimune® patent granted
US Skimune® patent granted
Skimune® Epi launced
EU Skimune® 3D patent granted
3D Innervated skin model launch